

## 2022 Special Vaccine Order Form Fax: 705-792-3835 or Email: Vaccineorders@smdhu.org

Date:					
Facility Name:		Phone #:	Ext: Facility Fax #:		
Facility Contact:		# of Fridg	ges: Type: □ Bar □ Domestic □ Purpose Built		
Wednesday	Wednesday 3 pm for pure the previous 4 week		<ul> <li>Coolers must be between 2 - 8 °C for vaccine to be released</li> <li>Vaccine order inquiries ext. 8808</li> </ul>		
	e PUBLICLY FUNDED ween doses (product		HEDULES FOR ONTARIO (January 2021) for # of eligible doses and d below).		
Initials (First. L	ast):		DOB (YYYY/MM/DD):		
Vaccine Name	Product / Description	Dose # in Series Requested	Eligibility Criteria (check all that apply)		
Bexsero®	Meningococcal B	Dose:	Age 2 months through 17 years:  □ Functional or anatomic asplenia □ Complement, properdin, factor D deficiency, or primary antibody deficiency □ Cochlear implant recipient (pre/post implant) □ Acquired complement deficiency (e.g., receiving eculizumab) □ HIV		
Nimenrix®	Meningococcal C-ACYW135	Dose:	Age 9 months through 55 years:  □ Functional or anatomic asplenia □ Complement, properdin, factor D deficiency or primary antibody deficiency □ Cochlear implant recipient (pre/post implant) □ Acquired complement deficiency (e.g., receiving eculizumab) □ HIV		
		Dose:  ☐ 1  (See Table 15)	Age ≥ 56 years:  □ Functional or anatomic asplenia □ Complement, properdin, factor D deficiency or primary antibody deficiency □ Cochlear implant recipients (pre/post implant) □ Acquired complement deficiency (e.g., receiving eculizumab) □ HIV		
Location to be picked up (please check):					
☐ Barrie ☐	Collingwood	Cookstown	Midland VIM Order # (for office use only):		

**Confidentiality Notice:** 

The contents of the document(s) accompanying this facsimile transmission are confidential and intended only for use by the individual(s) named above. It may contain information that is privileged, confidential, or otherwise protected from disclosure. <u>Any review, dissemination or use of this transmission or its contents by persons other than the addressee is strictly prohibited.</u>

Vaccine Name	Product / Description	Dose # in Series Requested	Eligibility Criteria (check all that apply)	
Avaxim® / Havrix® / Vaqta®  Avaxim® Pediatric Havrix® Pediatric Vaqta® Pediatric	Hepatitis A	Dose:	Age ≥ 1 year:  ☐ Chronic liver disease (including hepatitis B and C) ☐ Persons engaging in intravenous drug use ☐ Men who have sex with men	
Recombivax HB® / Engerix-B®  Recombivax HB® Pediatric  Engerix-B® Pediatric	Hepatitis B □ Latex allergy	Dose:	Age ≥ 0 years:  Infant born to HBV-positive mothers:  Premature infant weighing < 2,000 grams at birth (4 doses)  Premature infant weighing ≥ 2000 grams at birth and full/post terms infants (3 doses)  Household or sexual contact of chronic carrier or acute cases (3 doses)  Individual engaging in intravenous drug use (3 doses)  Men who have sex with men, individual with multiple sex partners or history of sexually transmitted disease (3 doses)  Needle stick injury in a non-health care setting (3 doses)  Child < 7 years old whose family has immigrated from country of high prevalence for hepatitis B and who may be exposed to hepatitis B carriers through their extended family (3 doses)  Chronic liver disease including hepatitis C (3 doses)  Awaiting liver transplant ( 2 <sup>nd</sup> and 3 <sup>rd</sup> dose only)	
High Dose (Dialysis) Formulation Recombivax HB®	Hepatitis B	Dose:	Age ≥ 20 years:  Chronic renal disease or on dialysis Chronic liver disease Individuals awaiting liver transplant HIV	
Gardasil®	HPV	Dose: ☐ 1 ☐ 2 ☐ 3  (Table 10 and Table 11)	Males 9 to 26 years:  ☐ Men who have sex with men	
Location to be picked up (please check):  Barrie Collingwood Cookstown Midland VIM Order # (for office use only):				

**Confidentiality Notice:** 

The contents of the document(s) accompanying this facsimile transmission are confidential and intended only for use by the individual(s) named above. It may contain information that is privileged, confidential, or otherwise protected from disclosure. Any review, dissemination or use of this transmission or its contents by persons other than the addressee is strictly prohibited.